The XTrack System: Application and Advantage

Klimkait, Thomas

doi:10.1159/000332003

Cited by 3 publications

(2 citation statements)

References 15 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there are currently no clinically available entry inhibitors that target X4, a better understanding of the mechanisms that drive viral infection via X4 is of central relevance. Reliable genotypic tropism tests have been established for identifying the viral tropism and to dissect mixed virus populations .…”

Section: Introductionmentioning

confidence: 99%

Correlating HIV tropism with immunological response under combination antiretroviral therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Correlating HIV tropism with immunological response under combination antiretroviral therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In fact, both T-CUP and geno2pheno [coreceptor] have been developed to identify X4 viruses with highest sensitivity, so the use of too high FPR cut-offs should greatly overestimate X4 variants. Supporting our results, increasing evidence published in the latest years have also suggested the use of FPR cut-offs ranging 5.75%-10% in order to avoid exclusion of patients who would succeeded in their MVC treatment, while still guaranteeing a save administration of the drug [ 6 , 7 , 23 , 27 , 30 , 31 ].…”

Section: Discussionmentioning

confidence: 99%

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc

et al. 2015

View full text Add to dashboard Cite

ObjectivesWe analysed the impact of different parameters on genotypic tropism testing related to clinical outcome prediction in 108 patients on maraviroc (MVC) treatment.Methods87 RNA and 60 DNA samples were used. The viral tropism was predicted using the geno2pheno[coreceptor] and T-CUP tools with FPR cut-offs ranging from 1%-20%. Additionally, 27 RNA and 28 DNA samples were analysed in triplicate, 43 samples with the ESTA assay and 45 with next-generation sequencing. The influence of the genotypic susceptibility score (GSS) and 16 MVC-resistance mutations on clinical outcome was also studied.ResultsConcordance between single-amplification testing compared to ESTA and to NGS was in the order of 80%. Concordance with NGS was higher at lower FPR cut-offs. Detection of baseline R5 viruses in RNA and DNA samples by all methods significantly correlated with treatment success, even with FPR cut-offs of 3.75%-7.5%. Triple amplification did not improve the prediction value but reduced the number of patients eligible for MVC. No influence of the GSS or MVC-resistance mutations but adherence to treatment, on the clinical outcome was detected.ConclusionsProviral DNA is valid to select candidates for MVC treatment. FPR cut-offs of 5%-7.5% and single amplification from RNA or DNA would assure a safe administration of MVC without excluding many patients who could benefit from this drug. In addition, the new prediction system T-CUP produced reliable results.

show abstract

Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1

Bader

Däumer

Schöni‐Affolter

et al. 2016

CLINID

View full text Add to dashboard Cite

Our study demonstrates that X4-tropic HIV sharply declines in most patients during successful therapy, which indicates a preferential tropism-dependent provirus elimination in the immunocompetent host. The recently implemented World Health Organization strategies of immediate therapy initiation are fully in line with this gradual loss of X4 tropism during therapy. Moreover, the early use of coreceptor antagonists against the remaining CCR5-tropic viruses may be indicated.

show abstract

The XTrack System: Application and Advantage

Abstract: XTrack, a rapid, cost-effective diagnostic HIV tropism system, yields predictive results and dissects virus mixtures. It is based on the duplexing of patient samples with selective DNA probes, combined with sequence-based analysis and replicative phenotyping for ambiguous samples.

Cited by 3 publications

References 15 publications

Correlating HIV tropism with immunological response under combination antiretroviral therapy

Correlating HIV tropism with immunological response under combination antiretroviral therapy

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc

Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1

Contact Info

Product

Resources

About